Table 1.

Associations between specific biomarkers/aberrations and potential treatment sensitivities in pancreatic ductal adenocarcinoma.

Biomarker Type	Aberration	Potential Treatment Sensitivities	References
Genomic	Unstable genomes (>200 structural variation events)	Platinum-based agents, PARP inhibitor	Waddell et al, Nature 2015 (6) Golan et al, N Engl J Med 2019 (9)
Genomic	BRCA mutational signature; BRCA1/2, PALB2 mutations	Platinum-based agents, PARP inhibitor	Waddell et al, Nature 2015 (6) Golan et al, N Engl J Med 2019 (9) Raphael et al, Cancer Cell 2017 (19) Golan et al, Br J Cancer 2014 (21)
Gene expression	Basal-like/quasi-mesenchymal/squamous subtype	Gemcitabine, immune checkpoint blockade*	Collisson et al, Nat Med 2011 (25) Chan-Seng-Yue et al, Nat Genet 2020 (29) Hwang & Jagadeesh et al, bioRxiv 2020 (40) Porter et al, Proc Natl Acad Sci 2019 (65)
Gene expression	Classical-like epithelial subtype	FOLFIRINOX, Vitamin D, CD40 agonist*	Chan-Seng-Yue et al, Nat Genet 2020 (29) Hwang & Jagadeesh et al, bioRxiv 2020 (40) Porter et al, Proc Natl Acad Sci 2019 (65)
Cellular markers	ACTA2+ / LRRC15+ cancer associated myofibroblasts (myCAFs)	Losartan (TGF-β modulator)*	Elyada et al, Cancer Discov 2019 (44) Xu et al, Am J Pathol 2010 (50) Von Ahrens et al, J Hematol Oncol 2017 (51) Öhlund et al, J Exp Med 2017 (52) Ligorio et al, Cell 2019 (53) Dominguez et al, Cancer Discov 2020 (58)

^*Denotes lack of strong supporting evidence.